Cardiovascular
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
![](/-/media/editorial/headshots/corporate/s/soriot_pascal_az_ceo_2020_1200.jpg?rev=d4483d66261d4dbea7c960578641b09f&w=350&hash=048FD6B35B647B9ACA43080AD3B70C8D)
Farxiga Flying Off The Shelf At AstraZeneca
The UK major has raised its full-year sales and earnings forecast on strong demand in the second quarter for its cancer, rare disease and cardiovascular medicines.
![](/-/media/editorial/scrip/2021/08/sc2108_boehringer-ingelheim_2ej1nfb_1200.jpg?rev=3757ed42b42044b197759e4e42dffc83&w=350&hash=C4EC0814ED59D926E00F56CF64B18AF5)
Boehringer Looks To Revitalise Its Pipeline
With sales of its big sellers Jardiance and Ofev to start shrinking in the next few years, the German group is teeing up a suite of new drugs.
![](/-/media/editorial/scrip/2024/07/sc2407_digital3dheart_2306520083_1200.jpg?rev=c34630dbe74e4241a4e644f4b3a4b4be&w=350&hash=A0B0C0898779FB9812845E6534583496)
Cardurion Raises $260m To Advance First-In-Class Cardiovascular Drugs
The company’s series B venture capital will fund Phase IIb trials of PDE9 inhibitor CRD-750 in heart failure and a Phase IIa study of CaMKII inhibitor CRD-4730 in a rare arrhythmic disease.
![](/-/media/editorial/scrip/2024/06/sc2406_twohorserace_2408717541_1200.jpg?rev=b690a18bb8944c23905c290a0fa23c48&w=350&hash=07C0C469F6D4B0D3DC5E77B530EEB41D)
Arrowhead’s Focus On Plozasiran Intensifies Competition With Ionis
Arrowhead’s in-house, late-stage cardiovascular disease programs will center on triglyceride-lowering plozasiran while it seeks a partner to fund Phase III for cholesterol-reducing zodasiran.
![](/-/media/editorial/stock-images/biotech/sc2406_crisprgeneediting_2290113539_1200.jpg?rev=b5c05fe1c0404981a49989cd1468f13b&w=350&hash=5570423F3DBBD10979B37EBBC6488E03)
Intellia Becomes First To Show Potential For CRISPR Therapy Re-Dosing
The company presented data showing it is possible to safely and effectively re-dose its ATTR amyloidosis CRISPR/Cas9-based therapy.
![](/-/media/editorial/stock-images/diseases/sc2406_amyloidosis_1892780764_1200.jpg?rev=28f98879dc804fcaa990c30e4bf6c1c5&w=350&hash=628A26CAF9DBBACB2E221434940491D1)
Alnylam’s Amvuttra Market May See Tenfold Increase After Phase III Win
The company posted positive results from the HELIOS-B trial in patients with ATTR-CM, which represents a much larger population than the approved hATTR-PN indication.
![](/-/media/editorial/hbw-insight/hbw-stock-images/money-sack-198026720_1200.jpg?rev=532f0504023c4d76a03e26e30401363d&w=350&hash=04627AEE0D632EE0E7FCD4521CAED84F)
Cagrisema Leads The Charge For 2025
2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.
![](/-/media/editorial/stock-images/business/downward-red-arrow-1200-shutterstock_2147154855.jpg?rev=8be2725328dc493d8db25b3424a19996&w=350&hash=964DD56930D70EB81FAEB484A23917A4)
Aerovate Tanks On Trial Catastrophe
A disastrous Phase II miss for the pulmonary arterial hypertension candidate AV-101 leaves Aerovate drifting. Could Gossamer stand to benefit?
![](/-/media/editorial/buildings/corporate/a/arrowhead-1200-shutterstock_2205823015.jpg?rev=3c4b3cecb5674f02b1fc3523c5f277cf&w=350&hash=A09D9A82D777F63879EB41F699C8C8C0)
First Phase III Success Opens Up Cardiovascular Pathway For Arrowhead
Arrowhead could have its first in-house RNA therapy on the market by 2025, with big plans to expand its reach in cardiometabolic disease, following a pivotal trial hit.
![](/-/media/editorial/buildings/corporate/a/astrazeneca_1592976193_1200.jpg?rev=5b9985353d254af2a89090b38c000381&w=350&hash=D970290ABBA3D299FDE0B672E6330245)
First Results Keep AstraZeneca’s Hopes High For Oral PCSK9 Inhibitor
AstraZeneca is looking to speed AZD0780 into Phase III development after it achieved a 78% total LDL cholesterol reduction in a Phase I study when used in combination with rosuvastatin. The firm needs to play catch up with its oral rivals.
![](/-/media/editorial/scrip/2024/05/sc2405_heart_1278769930_1200.jpg?rev=823e6b0327b5429ba7d92ea79cb9d9e2&w=350&hash=5E48B0210608EAFA386AD6C138C1E968)
Cytokinetics’ Aficamten Data Could Be Best In Class, Cardiologists Say
The company released detailed data from the Phase III SEQUOIA-HCM trial testing the cardiac myosin inhibitor in patients with obstructive hypertrophic cardiomyopathy at Heart Failure 2024.
![](/-/media/editorial/scrip/2024/04/sc2404_sales_101018443_1200.jpg?rev=0af0e943675e4e1bac93e1426858a3ed&w=350&hash=1A6854691A92C0DBAB80C8FFA6B81577)
Merck Investors Keeping A Close Watch On Winrevair Uptake
Some patients have already been prescribed the new drug for pulmonary arterial hypertension but Merck & Co. did not provide any sales or guidance.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.